Delpazolid
- Generic Name
- Delpazolid
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C14H17FN4O3
- CAS Number
- 1219707-39-7
- Unique Ingredient Identifier
- 43EP6XV33E
- Background
Delpazolid (LCB01-0371) is under investigation in clinical trial NCT01554995 (A Clinical Study, Randomized, Double-blind, Placebo-controlled, Single Dose Study).
- Associated Conditions
- -
- Associated Therapies
- -
Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex
- Conditions
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- LigaChem Biosciences, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06004037
- Locations
- π°π·
Bundang Seoul National University Hospital, Seoul, Korea, Republic of
π°π·Asan Medical Center, Seoul, Korea, Republic of
π°π·Samsung Medical Center, Seoul, Korea, Republic of
A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia
- Conditions
- Interventions
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- LigaChem Biosciences, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05225558
- Locations
- π°π·
Korea University Ansan Hospital, Ansan, Korea, Republic of
π°π·Seoul National University Bundang Hospital, Seoul, Korea, Republic of
π°π·Severance Hospital, Seoul, Korea, Republic of
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- LigaChem Biosciences, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT04550832
- Locations
- πΉπΏ
Ifakara Health Institute, Bagamoyo, Tanzania
πΏπ¦The Aurum Institute Tembisa Clinical Research Centre, Tembisa, Gauteng, South Africa
πΏπ¦Clinical HIV Research Unit (CHRU) University of the Witwatersrand, Johannesburg, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.